Progress in the clinical classification of systemic sclerosis

Current Opinion in Rheumatology

Volumn 29, Issue 6, 2017, Pages 568-573

  Johnson, Sindhu R ^a,b,c  

^a TORONTO WESTERN HOSPITAL   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

classification criteria; scleroderma; subset; systemic sclerosis

Indexed keywords

CLINICAL CLASSIFICATION; DISEASE CLASSIFICATION; HUMAN; PREDICTIVE VALIDITY; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; SURVIVAL PREDICTION; SYSTEMIC SCLEROSIS; CLASSIFICATION;

HUMANS; SCLERODERMA, SYSTEMIC;

EID: 85030759633     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0000000000000443     Document Type: Review

References (46)

1. Johnson SR, Goek ON, Singh-Grewal D, et al. Classification criteria in rheumatic diseases: a review of methodologic properties. Arthritis Rheum 2007; 57:1119-1133.
2. Johnson SR. New ACR EULAR guidelines for systemic sclerosis classification. Curr Rheumatol Rep 2015; 17:32.
3. van den Hoogen F, Khanna D, Fransen J, et al. 2013 Classification criteria for systemic sclerosis: an American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. Ann Rheum Dis 2013; 72: 1747-1755.
4. Fransen J, Johnson SR, Van den Hoogen F, et al. Items for revised classification criteria in systemic sclerosis: results of a consensus exercise with the EULAR/ACR working group for classification criteria in systemic sclerosis. Arthritis Care Res 2012; 351-357.
5. van den Hoogen F, Khanna D, Fransen J, et al. 2013 Classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism Collaborative Initiative. Arthritis Rheum 2013; 65: 2737-2747.
6. Johnson S, Khanna D, Allanore Y, et al. Systemic sclerosis trial design moving forward. J Scleroderma Relat Disord 2016; 1:177-180.
7. Xu D, Hou Y, Zheng Y, et al. The 2013 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Systemic Sclerosis could classify systemic sclerosis patients at earlier stage: data from a Chinese EUSTAR center. PLoS One 2016; 11:e0166629.
8. Melchor S, Joven BE, Andreu JL, et al. Validation of the 2013 American College of Rheumatology/European League Against Rheumatism classification criteria for systemic sclerosis in patients from a capillaroscopy clinic. Semin Arthritis Rheum 2016; 46:350-355.
9. Jordan S, Maurer B, Toniolo M, et al. Performance of the new ACR/EULAR classification criteria for systemic sclerosis in clinical practice. Rheumatology (Oxford) 2015; 54:1454-1458.
10. Johnson SR, Feldman BM, Hawker GA. Classification criteria for systemic sclerosis subsets. J Rheumatol 2007; 34:1855-1863.
11. LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15:202-205.
12. Pope JE, Johnson SR. New classification criteria for systemic sclerosis (scleroderma). Rheum Dis Clin North Am 2015; 41:383-398.
13. Allanore Y. Limited cutaneous systemic sclerosis: the unfairly neglected subset. J Scleroderma Relat Disord 2016; 1:241-246.
14. Varga J, Hinchcliff M. Connective tissue diseases: systemic sclerosis: beyond limited and diffuse subsets? Nature reviews. Rheumatology 2014; 10: 200-202.
15. Singh JA, Solomon DH, Dougados M, et al. Development of classification and response criteria for rheumatic diseases. Arthritis Rheum 2006; 55: 348-352.
16. Felson DT, Anderson JJ. Methodological and statistical approaches to criteria development in rheumatic diseases. Baillieres Clin Rheumatol 1995; 9:253-266.
17. Goetz RH. The pathophysiology of progressive systemic sclerosis (generalized scleroderma) with special reference to changes in the fiscera. Cape Town Post Graduate Med Assoc 1945; 4:337-392.
18. Tuffanelli DL, Winkelmann RK. Diffuse systemic scleroderma. A comparison with acrosclerosis. Ann Intern Med 1962; 57:198-203.
19. Winterbauer RH. Multiple telengiectasia, Raynaud's phenomenon, sclerodactyly, and subcutaneous calcinosis: a syndrome mimicking hereditary hemorrhagic telengiectasia. Bull Johns Hopkins Hosp 1964; 114:361-383.
20. Barnett AJ, Coventry DA. Scleroderma. 1. Clinical features, course of illness and response to treatment in 61 cases. Med J Aust 1969; 1:992-1001.
21. Rodnan GP, Jablonska S, Medsger TA. Classification and nomenclature of progressive systemic sclerosis. Clin Rheumatic Dis 1979; 5:5-13.
22. Giordano M, Valentini G, Migliaresi S, et al. Different antibody patterns and different prognoses in patients with scleroderma with various extent of skin sclerosis. J Rheumatol 1986; 13:911-916.
23. Holzmann H, Sollberg S, Altmeyer P. Classification of progressive systemic scleroderma. Hautarzt 1987; 38:253-257.
24. Masi AT. Classification of systemic sclerosis (scleroderma): relationship of cutaneous subgroups in early disease to outcome and serologic reactivity. J Rheumatol 1988; 15:894-898.
25. Scussel-Lonzetti L, Joyal F, Raynauld JP, et al. Predicting mortality in systemic sclerosis: analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival. Medicine (Baltimore) 2002; 81:154-167.
26. Ferri C, Valentini G, Cozzi F, et al. Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore) 2002; 81:139-153.
27. Maricq HR, Valter I. A working classification of scleroderma spectrum disorders: a proposal and the results of testing on a sample of patients. Clin Exp Rheumatol 2004; 22:S5-S13.
28. Goetz R, Berne M. The pathophysiology of progressive systemic sclerosis (generalised scleroderma) with special reference to changes in the viscere. Clin Proc 1945; 4:337-392.
29. Barnett AJ, Miller M, Littlejohn GO. The diagnosis and classification of scleroderma (systemic sclerosis). Postgrad Med J 1988; 64:121-125.
30. Burgos-Vargas R, Martinez-Cordero E, Reyes-Lopez PA, Herrera-Esparza R. Antibody pattern and other criteria for diagnosis and classification of PSS. J Rheumatol 1988; 15:153-154.
31. Silman AJ. Scleroderma and survival. Ann Rheum Dis 1991; 50:267-269.
32. Black CM, Welsh KI, Maddison PJ, et al. HLA antigens, autoantibodies and clinical subsets in scleroderma. Br J Rheumatol 1984; 23:267-271.
33. Walker UA, Tyndall A, Czirjak L, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research (EUSTAR) group data base. Ann Rheum Dis 2007; 66:754-763.
34. Hesselstrand R, Scheja A, Akesson A. Mortality and causes of death in a Swedish series of systemic sclerosis patients. Ann Rheum Dis 1998; 57:682-686.
35. Kane GC, Varga J, Conant EF, et al. Lung involvement in systemic sclerosis (scleroderma): relation to classification based on extent of skin involvement or autoantibody status. Respir Med 1996; 90:223-230.
36. Wollheim FA. Classification of systemic sclerosis. Visions and reality. Rheumatology (Oxford) 2005; 44:1212-1216.
37. Matucci-Cerinic M, Bellando-Randone S, Lepri G, et al. Very early versus early disease: the evolving definition of the 'many faces' of systemic sclerosis. Ann Rheum Dis 2013; 72:319-321.
38. Minier T, Guiducci S, Bellando-Randone S, et al. Preliminary analysis of the Very Early Diagnosis of Systemic Sclerosis (VEDOSS) EUSTAR multicentre study: evidence for puffy fingers as a pivotal sign for suspicion of systemic sclerosis. Ann Rheum Dis 2014; 73:2087-2093.
39. Meyer OC, Fertig N, Lucas M, et al. Disease subsets, antinuclear antibody profile, and clinical features in 127 French and 247 US adult patients with systemic sclerosis. J Rheumatol 2007; 34:104-109.
40. Fertig N, Domsic RT, Rodriguez-Reyna T, et al. Anti-U11/U12 RNP antibodies in systemic sclerosis: a new serologic marker associated with pulmonary fibrosis. Arthritis Rheum 2009; 61:958-965.
41. Gorlova O, Martin JE, Rueda B, et al. Identification of novel genetic markers associated with clinical phenotypes of systemic sclerosis through a genomewide association strategy. PLoS Genet 2011; 7:e1002178.
42. van Bon L, Affandi AJ, Broen J, et al. Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis. N Engl J Med 2014; 370:433-443.
43. Johnson SR, Soowamber M, Fransen J, et al. There is a need for new systemic sclerosis subset classification criteria: a content analytic approach. Scand J Rheumatol 2017. (in press).
44. Wang B, Mezlini AM, Demir F, et al. Similarity network fusion for aggregating data types on a genomic scale. Nat Methods 2014; 11:333-337.
45. Nair R, Aggarwal R, Khanna D. Methods of formal consensus in classification/diagnostic criteria and guideline development. Semin Arthritis Rheum 2011; 41:95-105.
46. Johnson S, Hinchcliff M, Asano Y. Controversies: molecular vs. clinical systemic sclerosis classification. J Scleroderma Relat Disord 2016; 1: 277-285.